Boehringer-Ingelheim
Illumina Touts New Partnerships, Sequencing Technology at JP Morgan Healthcare Conference
The company saw strong uptake of its sequencing platforms in the clinical oncology market, a trend that is projected to continue in 2022.
Notable Labs Licenses Blood Cancer Drug Volasertib from Oncoheroes, Plans Clinical Trials
The firm will use its predictive platform to identify the best patient populations to evaluate in clinical trials of volasertib.
Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC
Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.
Boehringer Ingelheim's Afatinib Effective for Both Asian, Non-Asian Patients With EGFR-Mutated NSCLC
A pooled analysis of clinical trials and real-world data shows that the anti-tumor activity of Boehringer Ingelheim's TKI is unaffected by patients' ethnicity.
Final Analysis of Real-World Study Supports Sequential Gilotrif, Tagrisso for EGFR-Mutated NSCLC
The final GioTag data suggests a survival benefit with the regimen among patients with EGFR-mutant NSCLC harboring acquired T790M resistance mutations.